Blockbuster (anticipated yearly sales of more than 1 Billion) Drug Candidates: 1. Trexima for migraines...August FDA decision. The analysts are expecting approval. Glaxo-Smith-Klein is the developmental/commercialization partner. PN 400 Arthritis medicine...Phase 3 trials to start this year. Astra Zeneca (375 million contract) is the developmental/commercialization partner. PA 325 Safer (in terms of gastrointestinal damage) Aspirin. Stellar results from the first study were released on March 6th.

40% short , it may not cure cancer ,but it surely can give a bit more time on earth and with a better qaulity of life. I have seen the effect of rediation, my fathrer died from it , and now my best friend is undergoing the same.

AzaSite been approved . Inspire expects to launch AzaSite in the latter end of the third quarter, and projects the product will generate $30 million to $45 million in 2008 sales . Much more potential !

Recent accumulation by institution and insiders Vion has two agents in clinical trials. Cloretazine® (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine® (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies

possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

possible buy out? The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial.

Biopharmaceutical company IDM Pharma Inc. said Tuesday it will meet with a Food and Drug Administration advisory panel May 9 to discuss its application for Junovan. The drug -- its lead candidate -- is aimed at treating osteosarcoma, a type of malignant bone cancer, following surgical resection in combination with chemotherapy. IDM will meet with the Oncologic Drugs Advisory Committee, which will then give its recommendation to the FDA.